Senzar Asset Management Has Trimmed Its Halozyme Therapeutics (HALO) Position; Putnam Master Intermediate Income Trust (PIM) Has 1.08 Sentiment

January 14, 2018 - By Adrian Erickson

Senzar Asset Management Llc decreased Halozyme Therapeutics Inc (HALO) stake by 6.29% reported in 2017Q3 SEC filing. Senzar Asset Management Llc sold 257,074 shares as Halozyme Therapeutics Inc (HALO)’s stock rose 2.38%. The Senzar Asset Management Llc holds 3.83 million shares with $66.53 million value, down from 4.09 million last quarter. Halozyme Therapeutics Inc now has $2.87B valuation. The stock increased 1.50% or $0.3 during the last trading session, reaching $20.36. About 802,413 shares traded. Halozyme Therapeutics, Inc. (NASDAQ:HALO) has risen 44.89% since January 14, 2017 and is uptrending. It has outperformed by 28.19% the S&P500.

The stock decreased 0.42% or $0.02 during the last trading session, reaching $4.78. About 86,854 shares traded. Putnam Master Intermediate Income Trust (PIM) has risen 9.66% since January 14, 2017 and is uptrending. It has underperformed by 7.04% the S&P500.

Analysts await Halozyme Therapeutics, Inc. (NASDAQ:HALO) to report earnings on February, 27. They expect $0.67 earnings per share, up 419.05% or $0.88 from last year’s $-0.21 per share. HALO’s profit will be $94.51M for 7.60 P/E if the $0.67 EPS becomes a reality. After $0.02 actual earnings per share reported by Halozyme Therapeutics, Inc. for the previous quarter, Wall Street now forecasts 3,250.00% EPS growth.

Among 8 analysts covering Halozyme Therapeutics (NASDAQ:HALO), 5 have Buy rating, 0 Sell and 3 Hold. Therefore 63% are positive. Halozyme Therapeutics had 18 analyst reports since August 11, 2015 according to SRatingsIntel. Canaccord Genuity maintained the stock with “Buy” rating in Wednesday, July 26 report. Citigroup initiated the shares of HALO in report on Wednesday, November 18 with “Buy” rating. The company was maintained on Wednesday, November 8 by BMO Capital Markets. JMP Securities maintained Halozyme Therapeutics, Inc. (NASDAQ:HALO) rating on Tuesday, August 11. JMP Securities has “Market Outperform” rating and $22 target. Deutsche Bank initiated the stock with “Buy” rating in Thursday, November 3 report. Barclays Capital downgraded the stock to “Hold” rating in Wednesday, November 22 report. Barclays Capital maintained Halozyme Therapeutics, Inc. (NASDAQ:HALO) on Wednesday, February 24 with “Overweight” rating. JMP Securities maintained Halozyme Therapeutics, Inc. (NASDAQ:HALO) on Wednesday, March 9 with “Market Outperform” rating. The firm earned “Neutral” rating on Friday, January 6 by Citigroup. The company was maintained on Friday, September 16 by Piper Jaffray.

Investors sentiment decreased to 1.26 in Q3 2017. Its down 0.76, from 2.02 in 2017Q2. It is negative, as 14 investors sold HALO shares while 44 reduced holdings. 18 funds opened positions while 55 raised stakes. 118.53 million shares or 0.58% less from 119.22 million shares in 2017Q2 were reported. Rhumbline Advisers has 143,342 shares for 0.01% of their portfolio. Schwab Charles Investment stated it has 570,513 shares or 0.01% of all its holdings. State Of New Jersey Common Pension Fund D reported 0.02% stake. Torray Ltd Liability Corporation reported 0.05% in Halozyme Therapeutics, Inc. (NASDAQ:HALO). Hightower Limited Liability Corporation reported 0% of its portfolio in Halozyme Therapeutics, Inc. (NASDAQ:HALO). Alliancebernstein Ltd Partnership has 0% invested in Halozyme Therapeutics, Inc. (NASDAQ:HALO). Invesco Ltd owns 4.43M shares or 0.03% of their US portfolio. Walleye Trading Ltd Liability holds 0% or 21,700 shares. Pnc Financial Ser Grp holds 1,000 shares or 0% of its portfolio. Federated Pa reported 0% of its portfolio in Halozyme Therapeutics, Inc. (NASDAQ:HALO). 190,935 were reported by California State Teachers Retirement. Sg Americas Secs Ltd Liability has 0% invested in Halozyme Therapeutics, Inc. (NASDAQ:HALO). Intll Group Incorporated accumulated 0% or 79,210 shares. Sterling Glob Strategies Llc accumulated 22,000 shares or 1.56% of the stock. Smith Asset Lp reported 0.02% of its portfolio in Halozyme Therapeutics, Inc. (NASDAQ:HALO).

Sit Investment Associates Inc holds 1.12% of its portfolio in Putnam Master Intermediate Income Trust for 9.57 million shares. Investors Asset Management Of Georgia Inc Ga Adv owns 26,113 shares or 0.09% of their US portfolio. Moreover, Brick & Kyle Associates has 0.05% invested in the company for 14,300 shares. The Pennsylvania-based Wealthtrust Axiom Llc has invested 0.04% in the stock. Partnervest Advisory Services Llc, a California-based fund reported 13,416 shares.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>